FDA Panel To Weigh Adequacy Of Efficacy Evidence For Kalydeco Label Expansion
This article was originally published in The Pink Sheet Daily
Vertex is seeking approval for cystic fibrosis patients ages six years and older with the R117H mutation despite the pivotal trial’s primary endpoint failure and unfavorable pediatric subgroup results. Company believes totality of evidence supports approval and pediatric efficacy can be extrapolated from positive adult subgroup findings.
You may also be interested in...
Kalydeco, an oral CFTR potentiator, becomes the first approved drug to address the underlying cause of cystic fibrosis, rather than just treating the disease’s symptoms.
Failed confirmatory trials for PD-1/L-1 inhibitor indications raise questions about marginal response rates in single-arm trials used to support accelerated approval, Oncology Center of Excellence leaders say in NEJM article that explains why the agency is taking six of these indications to its Oncologic Drugs Advisory Committee.
Benefits of independence from exogenous insulin outweighed the risks from long-term immunosuppression necessary with the allogeneic pancreatic islet cellular therapy, majority of panelists said, but they urged the FDA to limit the indication to a very small subpopulation of patients.